
    
      Relapsed/refractory CD19 + acute lymphoblastic leukemia patients were randomly enrolled in
      this study to compare the efficacy and safety between two cohorts: 1. Humanized CD19 CAR-T
      cellsï¼› 2. Humanized CD19 CAR-T cells with CRS suppression technology.
    
  